Goodwin Guides IP for Pharmakon on Up to $200 Million Financing for Kestra Medical Technologies
The Life Sciences team advised Pharmakon Advisors, LP, on the intellectual property aspects of its five-year term loan facility providing Kestra Medical Technologies, Ltd., (Nasdaq: KMTS) with up to $200 million in non-dilutive financing. The financing includes a $75 million tranche funded at closing, up to $75 million in additional committed funding available upon the satisfaction of certain conditions, and a $50 million uncommitted acquisition tranche subject to Pharmakon's consent. The financing is intended to strengthen Kestra's balance sheet, reduce its cost of capital, and support its continued growth strategy.
Pharmakon Advisors, LP, is a leading investor in non-dilutive debt for the life sciences industry and serves as the investment manager for the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors have committed $12.7 billion across 81 investments.
The Goodwin team was led by Carl Morales, Kevin Grumberg, Xixi Sun, Clark Zhang, Tyler Garaffa, and Max Legg.
For more information, please read the announcement.